Invitae Corporation (NVTA)
NYSE: NVTA · IEX Real-Time Price · USD
0.534
-0.006 (-1.18%)
At close: Nov 27, 2023, 4:00 PM
0.530
-0.004 (-0.73%)
After-hours: Nov 27, 2023, 7:56 PM EST
Invitae Revenue
Invitae had revenue of $481.58M in the twelve months ending September 30, 2023, down -7.38% year-over-year. Revenue in the quarter ending September 30, 2023 was $121.24M, a -9.21% decrease year-over-year. In the year 2022, Invitae had annual revenue of $516.30M with 12.13% growth.
Revenue (ttm)
$481.58M
Revenue Growth
-7.38%
P/S Ratio
0.32
Revenue / Employee
$283,284
Employees
1,700
Market Cap
152.96M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 516.30M | 55.85M | 12.13% |
Dec 31, 2021 | 460.45M | 180.85M | 64.68% |
Dec 31, 2020 | 279.60M | 62.77M | 28.95% |
Dec 31, 2019 | 216.82M | 69.13M | 46.80% |
Dec 31, 2018 | 147.70M | 79.48M | 116.50% |
Dec 31, 2017 | 68.22M | 43.17M | 172.36% |
Dec 31, 2016 | 25.05M | 16.67M | 198.97% |
Dec 31, 2015 | 8.38M | 6.77M | 422.32% |
Dec 31, 2014 | 1.60M | 1.46M | 983.78% |
Dec 31, 2013 | 148.00K | - | - |
Dec 31, 2012 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
PetMed Express | 270.52M |
Nutex Health | 231.70M |
Sight Sciences | 82.85M |
Verrica Pharmaceuticals | 3.20M |
Lyra Therapeutics | 1.42M |
NVTA News
- 12 days ago - Aranscia Acquires YouScript from Invitae - Business Wire
- 19 days ago - Invitae Reports Third Quarter 2023 Financial Results - PRNewsWire
- 21 days ago - Invitae Launches Enhanced Chemistry of MRD Test to Better Serve Biopharmaceutical Clinical and Research Partnerships - PRNewsWire
- 26 days ago - Invitae to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023 - PRNewsWire
- 4 weeks ago - Landmark Study Reveals Magnitude of Uncertain Results in Clinical Genetic Testing for Hereditary Disease, Points to Evidence-Based Solutions to Reach Definitive Results - PRNewsWire
- 5 weeks ago - Invitae Appoints Dr. David Sholehvar as Chief Operating Officer - PRNewsWire
- 6 weeks ago - Rural Hospital System Demonstrates the Clinical Benefits of Implementing Universal Hereditary Cancer Testing in Patients with Breast Cancer - PRNewsWire
- 6 weeks ago - Invitae to Present Data at the National Society of Genetic Counselors 42nd Annual Conference That Supports Advancements in Medical Genomics - PRNewsWire